NPPA fixes retail price of 12 combo drugs including Aspirin, Atorvastatin, Metformin; Details
New Delhi: Through a recent notification, the apex drug price regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 12 drug formulations in combination with Aspirin, Atorvastatin, Metformin, Vildagliptin and others under the Drugs Prices Control Order (DPCO), 2013, exclusive of goods and services tax (GST).
The formulations whose prices have been fixed by NPPA include a combination of Atorvastatin, Aspirin and Clopidogrel Capsule, Vildagliptin and Metformin Tablet, Vildagliptin and Metformin Tablet (Vidalog M 500), Vildagliptin and Metformin Tablet (Vidalog M 1000) and so on.
various drugmakers including Mankind Pharma, Cipla, Emcure, Wockhardt and others are involved in manufacturing the said formulations under different brand names.
The formulations in the list are indicated for relieving allergy symptoms such as watery eyes, runny nose, itching eyes/nose, sneezing, hives, and itching; prevent fungal and yeast infection; for preventing blood clot and so on.
The details of the list of all 10 formulations released by NPPA read;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1. | Fluconazole Tablet | Each uncoated tablet contains: Fluconazole IP 300mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. | 16.16 |
2. | Atorvastatin + Aspirin + Clopidogrel Capsule | Each hard gelatine capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 20mg (As two white coloured film-coated tablets, each containing 10mg Atorvastatin Tablets IP), Aspirin IP 75mg (As enteric coated white coloured pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two brown coloured film-coated tablets, Each containing 37.5mg Clopidogrel tablet IP) | 1 Capsule | M/s Windlas Biotech Pvt. Ltd. / M/s Mankind Pharma Limited | 5.27 |
3. | Atorvastatin + Aspirin + Clopidogrel Capsule | Each hard gelatine capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 10mg (As Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) Aspirin IP 75mg (As enteric coated pellets) | 1 Capsule | M/s Synokem Pharmaceuticals Ltd. / M/s Emcure Pharmaceuticals Limited | 3.80 |
4. | Atorvastatin + Aspirin + Clopidogrel Capsule | Each hard gelatine capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 20mg (As Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) Aspirin IP 75mg (As enteric coated pellets) | 1 Capsule | M/s Synokem Pharmaceuticals Ltd. / M/s Emcure Pharmaceuticals Limited | 5.27 |
5. | Atorvastatin + Aspirin + Clopidogrel Capsule | Each hard gelatine capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 10mg (As Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) Aspirin IP 75mg (As enteric coated pellets) | 1 Capsule | M/s Synokem Pharmaceuticals Ltd. / M/s Cipla Limited | 3.80 |
6. | Atorvastatin + Aspirin + Clopidogrel Capsule | Each hard gelatine capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 20mg (As Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) Aspirin IP 75mg (As enteric coated pellets) | 1 Capsule | M/s Synokem Pharmaceuticals Ltd. / M/s Cipla Limited | 5.27 |
7. | Vildagliptin + Metformin Tablet | Each film-coated Tablet contains Vildagliptin 50mg, Metformin Hydrochloride IP 500mg, | 1 Tablet | M/s Mediforce Healthcare Pvt. Ltd. / M/s Mankind Pharma Limited | 22.77 |
8. | Vildagliptin + Metformin Tablet (Vidalog M 500) | Each film coated Tablet contains: Vildagliptin 50mg, Metformin Hydrochloride IP 500mg, | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Wockhardt Limited | 12.26 |
9. | Vildagliptin + Metformin Tablet | Each film-coated Tablet contains Vildagliptin 50mg, Metformin Hydrochloride IP 850mg, | 1 Tablet | M/s Mediforce Healthcare Pvt. Ltd. / M/s Mankind Pharma Limited | 22.75 |
10. | Vildagliptin + Metformin Tablet (Vidalog M 850) | Each film-coated Tablet contains Vildagliptin 50mg, Metformin Hydrochloride IP 850mg, | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Wockhardt Limited | 12.26 |
11. | Vildagliptin + Metformin Tablet | Each film-coated Tablet contains Vildagliptin 50mg, Metformin Hydrochloride IP 1000mg, | 1 Tablet | M/s Mediforce Healthcare Pvt. Ltd. / M/s Mankind Pharma Limited | 23.40 |
12. | Vildagliptin + Metformin Tablet (Vidalog M 1000) | Each film-coated Tablet contains Vildagliptin 50mg, Metformin Hydrochloride IP 1000mg, | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Wockhardt Limited | 12.53 |
Also Read: NPPA fixes retail price of 10 combo drugs including Metformin, Rosuvastatin; Details
The NPPA notice further adds;
- The manufacturer of above-mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.
- The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd